drugset / Trial / NCT06592599
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Timeline
- Start
- 2024-09-03
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |